Aging Frailty is estimated to affect between 7 to 12% of people 65 years of age and older. Aging Frailty results in increased fatigue, difficulty going about daily activities, decreased mobility, heightened risk of injury from falling, more frequent visits to the doctor and a general decrease in health without a definitive explanation of the cause.
An underlying trigger thought to be critically involved in Aging Frailty is chronic low-grade inflammation within the body. Such chronic inflammation can take a severe toll on the body and general health. This includes weakening of the immune system (immunosenescence).
Mesenchymal stem cell therapy has been shown to reduce inflammation, and promote endogenous tissue repair. We thus believe that LMSCs may be therapeutically beneficial to those with Aging Frailty, with long-term benefits of promoting increased mobility, strength and stamina, while also improving the immune systems and, ultimately, overall quality of life. We are currently multiple clinical studies to test the safety and efficacy of LMSCs in Aging Frailty.VIEW CLINICAL TRIALS
Alzheimer’s disease is a neurodegenerative disorder that leads to progressive memory loss and death. An estimated 5.3 million Americans are currently diagnosed, but there are few drugs available for treating Alzheimer’s disease, and none that affect the long-term progression of the disease. (Alzheimer’s Association ) Barring significant medical breakthroughs, as many as 16 million Americans could be afflicted by the year 2050.
An important component in the progression of Alzheimer’s disease is neuroinflammation. Given the abilities of mesenchymal stem cells to reduce inflammation and promote regeneration, LMSCs are being clinically evaluated in the treatment of Alzheimer’s disease. Prior studies in mouse models of Alzheimer’s disease support this approach.VIEW CLINICAL TRIALS
The Metabolic Syndrome (MetS) is a diagnosable condition characterized by the presence of a group of risk factors that increase a person’s chance of developing cardiovascular disease; Type II diabetes mellitus; serious macrovascular events, including myocardial infarction, stroke and angina; and death. These risk factors include obesity around the central area of the body, impaired glucose metabolism, dyslipidemia and hypertension. People with The Metabolic Syndrome are known to have bodies in a proinflammatory state, experiencing endothelial dysfunction and decreased circulating endothelial progenitor cells (EPCs). A high concentration of tumor necrosis factor alpha (TNF-alpha), proteins which promote inflammation has also been associated with this condition.
Allogenic human mesenchymal stem cells, such as LMSCs have been shown to inhibit inflammation, upregulate anti-inflammatory pathways and restore endothelial function. Our hypothesis holds that therapeutic intervention aimed at restoration of endothelial function and lowering TNF-alpha could potentially reduce the risk of developing Type II Diabetes Mellitus and vascular events. This could be of tremendous value. It is estimated that over 40% of adults in the U.S. have MetS, making consequences of the condition an enormous strain on the population and our healthcare system.VIEW CLINICAL TRIALS